Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Gary L. Pattee, Angela Genge, Philippe Couratier, Christian Lunetta, Gen Sobue, Masashi Aoki, Hiide Yoshino, Carlayne E. Jackson, James Wymer, Alejandro Salah & Sally Nelson. (2023) Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Expert Review of Neurotherapeutics 0:0, pages 1-8.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
Crystal Jing Jing Yeo & Zachary Simmons. (2018) Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 167-172.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Articles from other publishers (15)
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
Crossref
Benjamin Rix Brooks, Erik P. Pioro, Takeshi Sakata, Fumihiro Takahashi, Melissa Hagan & Stephen Apple. (2023) The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle & Nerve.
Crossref
Crossref
Yuan Lu, Julie Tzu-Wen Wang, Na Li, Xiaoqin Zhu, Yongjun Li, Sukhi Bansal, Yonglin Wang & Khuloud T. Al-Jamal. (2023) Intranasal administration of edaravone nanoparticles improves its stability and brain bioavailability. Journal of Controlled Release 359, pages 257-267.
Crossref
Crossref
Piotr Cysewski, Tomasz Jeliński & Maciej Przybyłek. (2023) Intermolecular Interactions of Edaravone in Aqueous Solutions of Ethaline and Glyceline Inferred from Experiments and Quantum Chemistry Computations. Molecules 28:2, pages 629.
Crossref
Crossref
Pedro Soares, Catia Silva, Daniel Chavarria, Filomena S.G. Silva, Paulo J. Oliveira & Fernanda Borges. (2023) Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Research Reviews 83, pages 101790.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Crossref
Hidetoshi Shimizu, Shinsuke Inoue, Mai Endo, Yoshinobu Nakamaru, Kaori Yoshida, Tomoko Natori, Masae Kakubari, Makoto Akimoto & Kazuoki Kondo. (2020) A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development 10:1, pages 46-56.
Crossref
Crossref
Yoshinobu Nakamaru, Masae Kakubari, Kaori Yoshida, Makoto Akimoto & Kazuoki Kondo. (2020) An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment. Clinical Therapeutics 42:9, pages 1699-1714.
Crossref
Crossref
Yoshinobu Nakamaru, Masae Kakubari, Kaori Yoshida, Makoto Akimoto, Vesna Todorovic, Thomas Greis & Kazuoki Kondo. (2020) Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Clinical Therapeutics 42:8, pages 1467-1482.e4.
Crossref
Crossref
Xia Chen, Zhuo Sun, Jiaqing Wang, Wu Liang, Xingquan Zhao, Yilong Wang & Yongjun Wang. (2020) Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation. Clinical Therapeutics 42:3, pages 428-438.
Crossref
Crossref
Andrea Fortuna, Matteo Gizzi, Luca Bello, Ilaria Martinelli, Cinzia Bertolin, Elena Pegoraro, Maurizio Corbetta & Gianni Sorarù. (2019) Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. Journal of the Neurological Sciences 404, pages 47-51.
Crossref
Crossref
Ranjeet Prasad Dash, R. Jayachandra Babu & Nuggehally R. Srinivas. (2018) Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clinical Pharmacokinetics 57:11, pages 1385-1398.
Crossref
Crossref
Max Hecht, Rūta Veigure, Lewis Couchman, Charlotte I S Barker, Joseph F Standing, Kalev Takkis, Hanno Evard, Atholl Johnston, Koit Herodes, Ivo Leito & Karin Kipper. (2018) Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis 10:15, pages 1229-1248.
Crossref
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref
Crossref